UPDATE -- BioAstra Unveils 'Twin Astra": Pioneering Deep-Space Medical Research Program Set to Transform Space Exploration and Earth-Based Medicine
The program was officially unveiled on Thursday, February 20, 2025, at The Explorers Club in New York City, and brought together top minds in space, science, and biotechnology.
About Twin Astra
Twin Astra is designed to unlock critical insights into human health through space-based research, driving breakthroughs that will impact both astronauts and Earth-based medicine. The program focuses on:
Twin Studies in Space: By studying genetically identical twins—one on Earth, the other in space—scientists will map the molecular, genetic, and physiological shifts caused by space travel.
Medical Breakthroughs: This research will accelerate advancements in precision medicine, aging, cancer treatment, and regenerative therapies.
Space Exploration & Human Resilience: The findings will pave the way for safer, long-duration space missions to the Moon, Mars, and beyond.
'By harnessing space as a biomedical testing ground, Twin Astra will redefine our understanding of human resilience in extreme environments,' said Professor Chris Mason, BioAstra Board Chair. 'This research is crucial for protecting astronauts and unlocking medical discoveries that will benefit life on Earth and beyond.'
Launch Event: February 20, 2025
This exclusive gathering brought together astronauts, biotech leaders, philanthropists, investors, and innovators to explore the program's groundbreaking potential.
'Twin Astra represents the next frontier of biomedical discovery,' said Savi Glowe, BioAstra CEO. 'By pushing the limits of human biology in space, we are opening doors to new treatments, technologies, and insights that will redefine healthcare for generations to come.'
Event Highlights:
Event Details:
Date: Thursday, February 20
Time: 6:00 PM – 8:00 PM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer
Veteran commercial leader to scale AI-enabled NAMkind™ liver and intestine toxicology services in a rapidly growing market SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the 'Company' or 'VivoSim Labs'), a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine, announced today that it has appointed Tony Lialin as its Chief Commercial Officer. Mr. Lialin brings more than two decades of experience turning breakthrough life science platforms into scalable, predictable revenue. He has built commercial teams from the ground up, forged strategic pharma partnerships, and helped scale multiple businesses that were later acquired by leading industry players. At VivoSim Labs, he will lead go-to-market strategy, partnerships, and the expansion of the Company's San Diego-based services that combine organ-specific 3D models with AI-driven analytics to deliver decision-ready insights earlier in development. Market Opportunity: According to an internal analysis conducted by VivoSim Labs in July 2025, the global combined liver and gastrointestinal in-vitro models and toxicology services market generated $641M in revenue in 2024. Services represented 53.1% of revenue vs. models at 46.9% of revenue. The United States accounted for $325M (50.8%) of the global market for liver toxicology models and services. Adoption of 3D human-relevant systems is rising, with the global in vitro liver model market growing at 5.9% CAGR from 2020 to 2024. Category Tailwinds: Biopharma sponsors are accelerating the use of non-animal new approach methodologies (NAMs). Regulatory momentum, including the FDA Modernization Act 2.0 (2022), supports validated alternatives and is catalyzing broader adoption of human-relevant in vitro models for ADME and toxicology. How AI Helps: VivoSim Labs applies AI to quantify multi-parametric toxicity signatures across liver and intestinal organoid assays. By improving signal-to-noise in dose-response analyses, the platform helps project teams prioritize candidates and plan studies with greater confidence. 'VivoSim Labs sits at the intersection of biology and AI. Our NAMkind™ models are designed to answer make-or-break questions earlier,' said Tony Lialin, Chief Commercial Officer, VivoSim Labs. 'We will scale a high-touch, consultative service from our San Diego lab so pharma and biopharma teams get decision-ready toxicology insights that aim to streamline pre-IND decision-making and reduce late-stage surprises.' 'Tony has a rare track record of turning disruptive science into durable commercial engines,' said Keith Murphy, Executive Chairman, VivoSim Labs. 'As sponsors move rapidly to 3D, human-relevant models, they want a partner—not just a plate or a protocol—to guide critical decisions. Tony knows how to build the solutions that our customers need.' About VivoSim Labs VivoSim Labs, Inc. ("VivoSim" and the 'Company'), is a pharmaceutical and biotechnology services company that is focused on providing testing of drugs and drug candidates in three-dimensional ('3D') human tissue models of liver and intestine. The Company offers partners liver and intestinal toxicology insights using its new approach methodologies ("NAM") models. The Company anticipates accelerated adoption of human tissue models following the U.S. Food and Drug Administration ('FDA") announcement on April 10, 2025 to refine animal testing requirements in favor of these non-animal NAM methods. VivoSim Labs operates from San Diego, CA. Visit Forward-Looking Statements Any statements contained in this press release that do not describe historical facts constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Forward-looking statements include statements regarding expansion of the Company's San Diego-based services; the potential for the Company's organ-specific 3D models and AI-driven analytics to deliver decision-ready insights earlier in development; the market opportunity and market size of gastrointestinal in-vitro models and toxicology services; and the ability of the Company's services to improve signal-to-noise in dose-response calls or help project teams prioritize candidates and studies with greater confidence. Such forward-looking statements are not guarantees of performance and actual actions or events could differ materially from those contained in such statements. These risks and uncertainties and other factors are identified and described in more detail in the Company's filings with the SEC, including its Annual Report on Form 10-K filed with the SEC on June 5, 2025, as such risk factors are updated in its most recently filed Quarterly Report on Form 10-Q filed with the SEC on August 12, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that the Company may issue in the future. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events, or circumstances or to reflect the occurrence of unanticipated events. ContactInvestor Relationsinfo@ Labs, in to access your portfolio
Yahoo
8 hours ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025
Breakthrough Epigenetic Modulator LB-100 Targets Ovarian Clear Cell Carcinoma, Advanced Soft Tissue Sarcoma, and MSS Metastatic Colon Cancer DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the epigenetic modulation of key cellular pathways. 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including multiple trial results, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 in combination with carboplatin and paclitaxel is designed to overcome platinum resistance by leveraging LB-100's synergistic enhancement of DNA damage and impaired repair in tumor cells. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains poor. LIXTE's Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Ongoing dose escalation, with expansion cohort enrollment underway Upcoming Milestone: Progression-free survival (PFS) and objective response rate (ORR) update late Q3 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with immune checkpoint blockade and chemotherapy, seeking to overcome immune resistance in this cold tumor type. Status: Actively recruiting Upcoming Milestone: Initial biomarker and response data anticipated in Q4 2025 Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma, pancreatic, and lung cancers Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. CONTACT:24/7 Market NewsEditor@ Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, the popularity and/or competitive success of the Company's acquired football and other sports teams, the Company's ability to attract players and staff for acquired clubs, unsuccessful acquisitions or other strategic transactions, the possibility of a decline in the popularity of football or other sports, the Company's ability to expand its fanbase, sponsors and commercial partners, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
Yahoo
a day ago
- Yahoo
Mexico Microcarrier Market Trends and Company Analysis Report 2025-2033 Featuring BD, Thermo Fisher Scientific, Merck, Eppendorf, Danaher, Sartorius, Bio Rad, Corning, Lonza Group, Getinge
The Mexico Microcarrier Market is poised for significant growth, projected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, achieving a CAGR of 7.66% from 2025 to 2033. Key drivers include increased investment in regenerative medicine and cell therapy, rising demand for cell-based vaccines and biologics, and technological advancements in cell culture efficiency. Mexico's biopharmaceutical sector expansion, supported by enhanced bioprocessing infrastructure and strategic public-private partnerships, further bolsters this growth. Emerging challenges include high setup costs and complex regulatory requirements, offering opportunities for innovation and collaboration. Mexican Microcarrier Market Dublin, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The "Mexico Microcarrier Market to Reach US$ 77.65 Million by 2033 - 7.66% CAGR Growth Driven by Biopharma Demand" report has been added to Mexico Microcarrier Market is expected to reach US$ 77.65 million by 2033 from US$ 39.96 million in 2024, with a CAGR of 7.66% from 2025 to 2033. Growing investment in regenerative medicine and cell therapy, growing demand for cell-based vaccines and biologics, technological advancements in culture efficiency, and expansion of biopharmaceutical research and development in Mexico. Mexico's growing biopharmaceutical and biotechnology industries depend heavily on the microcarrier industry. The large-scale manufacturing of biologics, vaccines, and cell treatments depends on microcarriers, which are tiny, spherical particles that promote the proliferation of adherent cells in bioreactors. As Mexico looks to improve its local manufacturing capabilities in response to growing healthcare demands and the need for medical product self-sufficiency, these applications become more and more market is expanding due to a number of causes. Research and development expenditures, along with the nation's strategic efforts to strengthen its biomanufacturing infrastructure, are essential. The need for effective cell culture systems is further fueled by the aging population and the rising incidence of chronic diseases, which increase demand for cutting-edge treatment solutions. Additionally, Mexico has easier access to cutting-edge biotechnologies, such as microcarrier-based cell culture systems, thanks to its involvement in international health programs and collaborations with foreign the encouraging growth trajectory, the Mexican microcarrier market still confronts obstacles including the requirement for specialized technological know-how and the development of strong regulatory frameworks to guarantee the quality and safety of the products. Nonetheless, these difficulties offer chances for creativity and cooperation. These problems can be resolved by creating training initiatives, establishing regulatory guidelines, and encouraging public-private partnerships. This will create an atmosphere that is favorable for the expansion of the microcarrier market and the larger biopharmaceutical sector in Factors Driving the Mexico Microcarrier Market Growth Increasing Demand for Cell Therapy and BiopharmaceuticalsMicrocarrier systems are in high demand due to Mexico's growing biopharmaceutical industry, which includes the manufacture of vaccines, biologics, and cell treatments. Businesses are depending more and more on microcarriers to sustain high density adherent cell cultures in bioreactors as local R&D becomes more intense and manufacturing capacity need is particularly noticeable in the creation of therapeutic proteins, monoclonal antibodies, and items related to regenerative medicine. Scalable and effective cell culture is made possible by microcarriers, which is necessary for the commercial production of biologics and sophisticated cell culture systems are now a vital enabling technology for Mexico's biomanufacturing efforts as the nation develops its capacities in these fields and aligns with international health Development and Manufacturing ExpansionMexico's bioprocessing infrastructure is being quickly strengthened through government sponsored initiatives and strategic public-private partnerships. The adoption of effective cell culture technologies is being fueled by investments in upstream bioprocessing facilities, automation, single use systems, and digital technology is also supported by the growth of industry academia partnership and regulatory modernization (e.g., COFEPRIS's digital transformation). These advancements promote easier technology transfer from research to production and improve the technical preparedness required for microcarrier is therefore better able to scale complex bioprocesses, which increases the accessibility of microcarriers for biotechnology companies, contract manufacturers, and academic institutions seeking to increase their capacity for and Technological Progress in MicrocarriersPerformance and scalability have been greatly enhanced by innovations in microcarrier design, such as surface functionalized beads, biodegradable materials, and compatibility with single use bioreactors. Manufacturers who prioritize quality and cost effectiveness are placing a greater value on enhanced features like increased yield, better cell adhesion, and lower contamination developments, when combined with automation, intelligent sensor integration, and digital process control, reduce human error and streamline production. Modern microcarrier formats are becoming feasible choices for biomanufacturers and researchers nation wide due to Mexico's rising alignment with international industry trends and the country's expanding adoption of state of the art bioprocessing in the Mexico Microcarrier Market Expensive Startup and Ongoing CostsMicrocarrier based cell culture system deployment requires a large financial outlay, especially for equipment such as bioreactors, single use systems, and associated infrastructure. Traditional planar culture techniques are still less expensive at lower scales because they require less like microcarrier beads make up a significant portion of the continuous expenses for microcarrier setups, which frequently require tens or even hundreds of thousands of dollars in capital expenditure. GMP grade, high quality microcarriers can account for 20-25% of total consumable financial barriers, in addition to media supplies and labor training, make the technology hard to adopt in Mexico, where a large number of biotech companies and academic institutions have tight budgets. Despite the long term productivity and efficiency benefits of microcarriers, this hinders scale of Regulations and Documentation NeedsUnder the General Health Law, COFEPRIS is in charge of regulating microcarrier based cell culture in Mexico, particularly when it is meant for clinical or therapeutic applications. In accordance with ICH guidelines, businesses are required to compile comprehensive Common Technical Document (CTD) dossiers that include clinical, non clinical, and quality is necessary to adhere to Official Mexican Standards (such as NOM?257?SSA1?2014, NOM?059?SSA1?2015), especially those that deal with GMP, bio comparability, and safety assessment. Microcarrier systems need to be thoroughly validated, which includes testing for batch uniformity, sterility, and cell material obstacles to commercialization include the burden of complicated documentation and testing, changing regulations, and unclear advanced therapeutic standards. Market access may be delayed, more expensive, and unclear for entities without local regulatory partnerships or past dossier experience. Company Analysis: Overview, Key Persons, Recent Developments, SWOT Analysis, Revenue Analysis Thermo Fisher Scientific Merck KGaA Eppendorf AG Danaher Corporation Sartorius AG Bio Rad Laboratories, Inc. Corning Inc. Lonza Group Getinge Becton, Dickinson and Company Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $39.96 Million Forecasted Market Value (USD) by 2033 $77.65 Million Compound Annual Growth Rate 7.6% Regions Covered Mexico Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Mexico Microcarrier Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Product Type6.2 By Application6.3 By End User6.4 By Region7. Product Type7.1 Consumables7.1.1 Microcarrier Beads7.1.2 Media & Reagents7.2 Equipment8. Application8.1 Cell Therapy8.1.1 Market Analysis8.1.2 Market Size & Forecast8.2 Vaccine Manufacturing8.3 Others9. End User9.1 Pharmaceutical & Biotechnology Companies9.2 Contract Research Organizations & Contract Manufacturing Organizations9.3 Academic & Research Institutes10. Region10.1 Northern Mexico10.2 Central Mexico10.3 Southern Mexico10.4 Others11. Value Chain Analysis12. Porter's Five Forces Analysis12.1 Bargaining Power of Buyers12.2 Bargaining Power of Suppliers12.3 Degree of Competition12.4 Threat of New Entrants12.5 Threat of Substitutes13. SWOT Analysis13.1 Strength13.2 Weakness13.3 Opportunity13.4 Threats14. Pricing Benchmark Analysis14.1 Thermo Fisher Scientific14.2 Merck KGaA14.3 Eppendorf AG14.4 Danaher Corporation14.5 Sartorius AG14.6 Bio-Rad Laboratories, Inc.14.7 Corning Inc.14.8 Lonza Group14.9 Getinge14.10 Becton, Dickinson and Company15. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Mexican Microcarrier Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
